ID

30370

Descrizione

https://clinicaltrials.gov/ct2/show/NCT00486954 Study ID: 104578 Clinical Study ID: EGF104578 Study Title: A Randomized, Multicenter, Open-label, Phase III Study of Lapatinib (GW572016) in Combination with weekly Paclitaxel versus weekly Paclitaxel alone in the second line treatment of ErbB2 amplified Advanced Gastric Cancer Patient Level Data: Clinicaltrials.gov Identifier: NCT00486954 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Product Sponsorship Transferred to Novartis Generic Name: lapatinib Trade Name: Tyverb,Tykerb,Tycerb Study Indication: Neoplasms, Gastrointestinal Tract CRF Seiten: 1288-1609

collegamento

https://clinicaltrials.gov/ct2/show/NCT00486954

Keywords

versioni (1)
  1. 30/05/18 30/05/18 - Halim Ugurlu
Titolare del copyright

GlaxoSmithKline (GSK)

Caricato su

30 maggio 2018

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

NCT00486954_Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer

Inglese

Investigational Product Compliance-Lapatinib, Investigational Product Discontinuation

1 moduli  
Investigational Product Compliance-Lapatinib
Descrizione

Investigational Product Compliance-Lapatinib

Alias
UMLS CUI-1
C0304229
UMLS CUI-2
C1321605
Date Investigational Product dispensed
Descrizione

Date Investigational Product dispensed

Tipo di dati

date

Alias
UMLS CUI [1,1]
C0011008
UMLS CUI [1,2]
C0947323
UMLS CUI [1,3]
C0304229
Total Number Dispensed
Descrizione

Total Number Dispensed

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0805077
UMLS CUI [1,2]
C0304229
Date investigatinal Product returned
Descrizione

Date investigatinal Product returned

Tipo di dati

date

Alias
UMLS CUI [1,1]
C0013230
UMLS CUI [1,2]
C2826249
Total number returned
Descrizione

Total number returned

Tipo di dati

text

Alias
UMLS CUI [1,1]
C2699071
UMLS CUI [1,2]
C0039225
Investigational Product Discontinuation
Descrizione

Investigational Product Discontinuation

Alias
UMLS CUI-1
C0304229
UMLS CUI-2
C0457454
Investigational Product
Descrizione

Investigational Product

Tipo di dati

integer

Alias
UMLS CUI [1]
C0304229
Was the investigational product stopped permanently before the end of the scheduled treatment period?
Descrizione

Investigational product stopped permanently before the end of the scheduled treatment period

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0304229
UMLS CUI [1,2]
C0457454
If yes, specify the primary reason the investigational product was stopped
Descrizione

Specify the primary reason the investigational product was stopped

Tipo di dati

integer

Alias
UMLS CUI [1,1]
C0392360
UMLS CUI [1,2]
C0304229
UMLS CUI [1,3]
C0457454
Ritorna all'inizio della pagina

Similar models

Investigational Product Compliance-Lapatinib, Investigational Product Discontinuation

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Investigational Product Compliance-Lapatinib
C0304229 (UMLS CUI-1)
C1321605 (UMLS CUI-2)
Date Investigational Product dispensed
Item
Date Investigational Product dispensed
date
C0011008 (UMLS CUI [1,1])
C0947323 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,3])
Total Number Dispensed
Item
Total Number Dispensed
text
C0805077 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
Date investigatinal Product returned
Item
Date investigatinal Product returned
date
C0013230 (UMLS CUI [1,1])
C2826249 (UMLS CUI [1,2])
Total number returned
Item
Total number returned
text
C2699071 (UMLS CUI [1,1])
C0039225 (UMLS CUI [1,2])
Item Group
Investigational Product Discontinuation
C0304229 (UMLS CUI-1)
C0457454 (UMLS CUI-2)
Item
Investigational Product
integer
C0304229 (UMLS CUI [1])
Investigational Product
Code List
Investigational Product
CL Item
Lapatinib (1)
CL Item
Paclitaxel (2)
Investigational product stopped permanently before the end of the scheduled treatment period
Item
Was the investigational product stopped permanently before the end of the scheduled treatment period?
boolean
C0304229 (UMLS CUI [1,1])
C0457454 (UMLS CUI [1,2])
Item
If yes, specify the primary reason the investigational product was stopped
integer
C0392360 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
C0457454 (UMLS CUI [1,3])
Specify the primary reason the investigational product was stopped
Code List
If yes, specify the primary reason the investigational product was stopped
CL Item
Adverse evetn, record details on the Non-Serious Adverse Events or Serious Adverse Events forms as appropriate (1)
CL Item
Lost to follow-up (2)
CL Item
Protocol violation (3)
CL Item
Subject decided to withdraw from the study (4)
CL Item
Sponsor termined study (6)
CL Item
Disease progression (7)
CL Item
Death (25)
CL Item
Subject decided to withdraw from IP but is to be followed for survival per protocol (27)
CL Item
Other, Specify (0)
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial